UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for atrial fibrillation (AF) in the United Kingdom. Explore treatment pathways including anticoagulation, catheter ablation, and left atrial appendage closure.
Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting over 1.5 million people in the UK. It causes an irregular and often fast heartbeat, increasing stroke risk by 5 times. Types include paroxysmal (comes and goes), persistent (sustained episodes), and permanent (continuous). Prevalence increases with age, and many people are undiagnosed.
Treatment focuses on two goals: stroke prevention and rhythm/rate control. Stroke prevention: anticoagulants (DOACs like apixaban, rivarelbaban, edoxaban) are preferred over warfarin. Left atrial appendage closure (Watchman device) for patients who cannot take anticoagulants. Rhythm control: antiarrhythmic drugs (flecainide, amiodarone), electrical cardioversion, and catheter ablation (pulmonary vein isolation).
Catheter ablation has become a key treatment for symptomatic AF. Techniques include radiofrequency ablation, cryoablation, and pulsed field ablation (PFA, the newest technology). PFA offers faster procedures with less collateral tissue damage. Trials are exploring ablation plus antiarrhythmic therapy, earlier intervention in paroxysmal AF, and ablation for heart failure patients with AF.
Active UK AF trials include: novel anticoagulants with improved safety profiles, pulsed field ablation devices, mapping and AI-guided ablation strategies, left atrial appendage closure devices, arrhythmia detection wearables, and combination approaches (ablation + drug therapy). Many trials are available through NHS cardiology and electrophysiology centres.
Free AI-powered matching - no signup required
Search AF Trials →